• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺特异性抗原速率:临床应用的系统评价

PSA velocity: a systematic review of clinical applications.

作者信息

Loughlin Kevin Raymond

机构信息

Division of Urology, Department of Surgery, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA.

出版信息

Urol Oncol. 2014 Nov;32(8):1116-25. doi: 10.1016/j.urolonc.2014.04.010. Epub 2014 Jun 25.

DOI:10.1016/j.urolonc.2014.04.010
PMID:24974369
Abstract

BACKGROUND

The value of prostate-specific antigen (PSA) for screening and management of prostate cancer (CaP) continues to engender much controversy in the medical and lay literature. This review is intended to critically analyze the literature to assess the utility of adding the calculation of PSA velocity (PSAV) in the screening and management of CaP.

METHODS

A systematic review of electronic databases including Medline PaperChase, PubMed, and Scopus was conducted to identify English-language studies in the peer-reviewed literature from 1992 to 2013. The free text search was extended by adding the following keywords: prostate cancer, screening, surgery, radiation therapy, active surveillance, and PSAV. All matches from the searches were read, and the articles pertinent to an analysis of PSAV in clinical practice were included in this review.

RESULTS

The design of much of the recent published literature on PSAV does not conform to the original description of PSAV or to the published guidelines regarding the number of PSA values and the interval of time over which the PSA values are obtained. This heterogeneity of definition is the source of much of the controversy regarding the clinical applications of PSAV. The preponderance of evidence suggests that there is high collinearity between PSA and PSAV and therefore the calculation of PSAV adds little to the measurement of PSA level.

CONCLUSIONS

PSAV calculation has been advocated by many investigators as a strategy to improve the screening and clinical management of patients with CaP. However, when PSAV definitions are rigorously applied, its calculation does not significantly enhance the clinical performance of PSA alone.

摘要

背景

前列腺特异性抗原(PSA)在前列腺癌(CaP)筛查及管理中的价值在医学及大众文献中仍备受争议。本综述旨在批判性分析文献,以评估在CaP筛查及管理中增加PSA速率(PSAV)计算的效用。

方法

对包括Medline PaperChase、PubMed和Scopus在内的电子数据库进行系统综述,以识别1992年至2013年同行评审文献中的英文研究。通过添加以下关键词扩展自由文本搜索:前列腺癌、筛查、手术、放射治疗、主动监测和PSAV。阅读搜索到的所有匹配项,并将与临床实践中PSAV分析相关的文章纳入本综述。

结果

近期许多关于PSAV的已发表文献的设计不符合PSAV的原始描述,也不符合关于PSA值数量及获取PSA值时间间隔的已发表指南。这种定义的异质性是PSAV临床应用诸多争议的根源。大量证据表明,PSA与PSAV之间存在高度共线性,因此PSAV的计算对PSA水平测量的增加作用不大。

结论

许多研究者主张计算PSAV,作为改善CaP患者筛查及临床管理的一种策略。然而,当严格应用PSAV定义时,其计算并不能显著提高单独PSA的临床性能。

相似文献

1
PSA velocity: a systematic review of clinical applications.前列腺特异性抗原速率:临床应用的系统评价
Urol Oncol. 2014 Nov;32(8):1116-25. doi: 10.1016/j.urolonc.2014.04.010. Epub 2014 Jun 25.
2
Screening for prostate cancer.前列腺癌筛查
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.
3
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
4
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
5
Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.使用经典和新型生物标志物作为局限性前列腺癌的预后危险因素:一项系统综述。
Health Technol Assess. 2009 Jan;13(5):iii, xi-xiii 1-219. doi: 10.3310/hta13050.
6
Lycopene for the prevention of prostate cancer.番茄红素用于预防前列腺癌。
Cochrane Database Syst Rev. 2011 Nov 9;2011(11):CD008007. doi: 10.1002/14651858.CD008007.pub2.
7
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.前列腺癌风险模型是否能提高 PSA 筛查的预测准确性?一项荟萃分析。
Ann Oncol. 2015 May;26(5):848-864. doi: 10.1093/annonc/mdu525. Epub 2014 Nov 17.
8
The measurement and monitoring of surgical adverse events.手术不良事件的测量与监测
Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220.
9
Chemotherapy for hormone-refractory prostate cancer.激素难治性前列腺癌的化疗
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005247. doi: 10.1002/14651858.CD005247.pub2.
10
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.局限性和局部晚期前列腺癌的新辅助和辅助激素治疗
Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD006019. doi: 10.1002/14651858.CD006019.pub2.

引用本文的文献

1
Relationships between holmium laser enucleation of the prostate and prostate cancer.钬激光前列腺剜除术与前列腺癌之间的关系。
Nat Rev Urol. 2023 Apr;20(4):226-240. doi: 10.1038/s41585-022-00678-y. Epub 2022 Nov 23.
2
Do prostate-specific antigen parameters have a similar role in predicting prostate cancer regardless of serum testosterone levels in men with gray-zone prostate-specific antigen levels?在前列腺特异性抗原水平处于灰色区域的男性中,无论血清睾酮水平如何,前列腺特异性抗原参数在预测前列腺癌方面是否具有相似作用?
Transl Androl Urol. 2022 Apr;11(4):421-429. doi: 10.21037/tau-21-1051.
3
Incidental Prostate Cancer from Prostate with Benign Biopsies: A Predictive and Survival Analysis from Cohort Study.
良性活检前列腺中的偶发性前列腺癌:一项队列研究的预测与生存分析
Int J Gen Med. 2022 Mar 10;15:2807-2816. doi: 10.2147/IJGM.S357368. eCollection 2022.
4
The influence of age on prostate cancer screening index.年龄对前列腺癌筛查指数的影响。
J Clin Lab Anal. 2022 Jan;36(1):e24098. doi: 10.1002/jcla.24098. Epub 2021 Nov 24.
5
Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.前列腺特异性抗原速度与接受主动监测治疗低危前列腺癌的非裔美国男性和非西班牙裔白种男性临床进展的相关性。
JAMA Netw Open. 2021 May 3;4(5):e219452. doi: 10.1001/jamanetworkopen.2021.9452.
6
The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions.前列腺特异性抗原速度(PSAV)、数值及增速与游离前列腺特异性抗原/总前列腺特异性抗原指数或比值与前列腺疾病之间的关联。
J Clin Med. 2020 Oct 23;9(11):3400. doi: 10.3390/jcm9113400.
7
Diagnosis of prostate cancer.前列腺癌的诊断。
Asian J Urol. 2019 Apr;6(2):129-136. doi: 10.1016/j.ajur.2018.11.007. Epub 2019 Feb 14.
8
Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.抗炎药物使用对 PSA 动力学及后续前列腺癌诊断的潜在影响:经前列腺活检的良性前列腺疾病黑人和白人患者的风险分层。
Prostate. 2019 Jul;79(10):1090-1098. doi: 10.1002/pros.23820. Epub 2019 May 2.
9
Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence.基于多种蛋白质和 microRNA 生物标志物的超声释放进行肿瘤特征分析:临床前和临床证据。
PLoS One. 2018 Mar 16;13(3):e0194268. doi: 10.1371/journal.pone.0194268. eCollection 2018.
10
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.具有遗传易感性男性的前瞻性前列腺癌筛查研究中的前列腺特异性抗原速度。
Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4.